Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BG00012 (dimethyl fumarate) vs placebo in pediatric relapsing-remitting multiple sclerosis
2014-005624-98Phase 3Terminated
- Sponsor
- Biogen
- Start
- Jul 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in multiple sclerosis (MS) comparing BG00012 (Tecfidera) BID with Placebo (2 arms). Primary endpoint: Time to first multiple sclerosis relapse. Started Jul 2015; status: terminated.
02
Drugs
dimethyl fumarate
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2014-005624-98.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-005624-98.